Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA grants regenerative medicine advanced therapy designation to CD34+ cell therapy

June 20, 2018

Positive interim phase II data presented for LB-1148 in patients undergoing major surgery

June 20, 2018

Marinus Pharmaceuticals initiates pivotal phase III Marigold Study of ganaxolone

June 20, 2018

Kazia Therapeutics presents preliminary phase I data for Cantrixil

June 20, 2018

DGKZ regulates muscle mass in remodeling and may be a target of therapies against muscle wasting

June 20, 2018

WindMIL Therapeutics completes series B financing to support development of MILs

June 20, 2018

NINDS grant supports AcuraStem's work in ALS

June 20, 2018

EDELWEISS phase IIb study of linzagolix achieves primary and secondary endpoints

June 20, 2018

First-in-human results reported for MK-1248 in advanced solid tumors

June 19, 2018

Alexion submits U.S. BLA for ALXN-1210 to treat PNH

June 19, 2018

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...